Neuromolecular Risk Factors for Obesity (PROSPECT)
Primary Purpose
Obesity
Status
Active
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
fMRI imaging
[11C]carfentanil PET scan
[18F]FMPEP-d2 PET scan
[18F]-FDG PET scan
Physical activity measures and fitness tests
Laboratory measurements
Questionnaires
Hyperinsulinemic euglycemic clamp
Sponsored by

About this trial
This is an interventional basic science trial for Obesity focused on measuring PET imaging, Cannabinoid receptor, Opioid receptor, Addiction, fMRI imaging
Eligibility Criteria
Inclusion Criteria:
Inclusion criteria for low-risk group:
- Male sex
- Age 20-35 years
- BMI 20-24 kg/m2
- Physical exercise > 4 hrs per week
- No maternal / paternal obesity OR maternal / paternal type 2 diabetes mellitus (T2DM)
Inclusion criteria for high-risk group:
- Male sex
- Age 20-35 years
- BMI 25 - 30 kg/m2
- Maternal / paternal obesity OR maternal / paternal T2DM
- Physical exercise < 4 hrs per week
Exclusion Criteria:
- Any chronic disease or medication that could affect glucose metabolism or neurotransmission
- History of anorexia nervosa, bulimia or other eating disorder (excl. common obesity)
- Smoking of tobacco, taking of snuffs, or use of narcotics
- Abusive use of alcohol
- Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
Sites / Locations
- Turku PET Centre (Turku University Hospital)
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Low-risk group
High-risk group
Arm Description
Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Outcomes
Primary Outcome Measures
Neuromolecular risk score for weight gain
Acquired with combining the measured BMI change in five years to measured alterations in brain function (see below).
Secondary Outcome Measures
Localization of on-going neural activity during various cognitive and affective tasks
Acquired with fMRI imaging
Brain and body glucose uptake
Acquired with PET imaging
Brain and body CB1 availability
Acquired with PET imaging
Brain MOR availability
Acquired with PET imaging
Genes regulating MOR (OPRM1) and D2R (DRD2) expression
Acquired with whole blood sample and DNA/RNA analysis
Genetic risk score from all known obesity-risk genes
Acquired with whole blood sample and DNA/RNA analysis
Behavioural patterns involving dysfunctional reward learning and inhibitory control
Acquired with following questionnaires: assessment of leisure-time physical activity (LTPA), Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire, Pain Sensitivity Questionnaire, DASS-21, PSS-10
Physical activity level
Acquired with Polar M600 GPS Sports Watch that study subjects wear for the measurement period
Maximal physical performance
The subjects will perform a maximal aerobic exercise test on a bicycle ergometer starting at the intensity of 50 W and followed by an increase of 30 W every 2 min until volitional exhaustion. Peak workload will be calculated as an average workload during the last 2 min of the test (weighted average will be used if the final stage is stopped prior the completion) and used as a measure of maximal performance of the subjects
Physical strength
Total physical strenght score is calculated from 1) countermovement jump test with a contact mat (flight time measured - jump height calculated), hand grip strength (measured in Newtons), sit-ups (number of repetitions in 30 s), and back extension (reps in 30 s)
BMI change in five years
Acquired with BMI of the study subjects measured in initial health check-up and once in every study year
Body adiposity
Acquired with BodPod device (Frisard, Greenway, & DeLany, 2005)
Full Information
NCT ID
NCT03106688
First Posted
March 5, 2017
Last Updated
December 16, 2021
Sponsor
Turku University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03106688
Brief Title
Neuromolecular Risk Factors for Obesity (PROSPECT)
Official Title
Detecting Neuromolecular Risk Factors for Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 4, 2017 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Turku University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this project is to characterize the neural and psychological mechanisms that contribute to development of obesity in the early adulthood. We address the neuromolecular risk factors for obesity using multi-modal molecular (positron emission tomography with) and functional (functional magnetic resonance imaging) neuroimaging in a prospective design. Normal weight adolescents with high versus low familial, genetic and psychological risk factors for obesity will be studied and followed for five years.
Detailed Description
Diet, nutrition, and physical exercise are critical factors in the maintenance of good health through the entire life course. However, in most western countries the annual increase in the prevalence and the severity of obesity and physical inactivity is substantial. Early detection of individuals with high risk for obesity is important, because reversing the obese state is very difficult. To prevent and treat obesity, it is necessary to characterize neural mechanisms supporting altered incentive motivation and food intake, and to build a comprehensive model of the interactions between neural, physiological, and psychological factors contributing to development and maintenance of obesity. This obviously calls for novel data analysis techniques allowing fusion analysis of neurobiological, physiological, and behavioural data, as well as screening the critical combination of biomarkers for obesity.
A total of sixty males (30 normal-weight, 30 with risk for developing obesity) are recruited into this prospective study. The subjects will undergo physical examination, physical fitness tests, physical activity measures, body tissue composition measurement, structural and functional magnetic resonance imaging of the brain and body (MRI & fMRI), and positron emission tomography (PET) with ligands [18F]-fluorodeoxyglucose ([18F]-FDG), [18-F]FMPEP, and [11C]carfentanil. Subjects' weight and physical condition will be followed up for 5 years.
In three interconnected work packages (WPs) we test three hypotheses derived from human and animal studies:
Altered reward and cognitive control functions in the brain predisposes some individuals to overeating and obesity.
Opioid system and reward circuit function provide feasible biomarkers for obesity risk.
Mobile tracking and behavioural paradigms tapping reward learning and inhibitory control can be used for unobtrusive and inexpensive detection of risk factors for obesity.
These studies will improve our understanding of the neural and psychological mechanisms of obesity and addictive disorders. This knowledge will translate into crucial knowledge for developing novel risk factor screening procedures, and novel pharmacological and psychological treatments for obesity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
PET imaging, Cannabinoid receptor, Opioid receptor, Addiction, fMRI imaging
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Low-risk group
Arm Type
Active Comparator
Arm Description
Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
Arm Title
High-risk group
Arm Type
Active Comparator
Arm Description
Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
Intervention Type
Diagnostic Test
Intervention Name(s)
fMRI imaging
Intervention Description
Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
Intervention Type
Diagnostic Test
Intervention Name(s)
[11C]carfentanil PET scan
Intervention Description
[11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
Intervention Type
Diagnostic Test
Intervention Name(s)
[18F]FMPEP-d2 PET scan
Intervention Description
[18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
Intervention Type
Diagnostic Test
Intervention Name(s)
[18F]-FDG PET scan
Intervention Description
Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.
Intervention Type
Diagnostic Test
Intervention Name(s)
Physical activity measures and fitness tests
Intervention Description
Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
Intervention Type
Diagnostic Test
Intervention Name(s)
Laboratory measurements
Intervention Description
Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
Intervention Type
Diagnostic Test
Intervention Name(s)
Questionnaires
Intervention Description
All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
Intervention Type
Diagnostic Test
Intervention Name(s)
Hyperinsulinemic euglycemic clamp
Intervention Description
Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
Primary Outcome Measure Information:
Title
Neuromolecular risk score for weight gain
Description
Acquired with combining the measured BMI change in five years to measured alterations in brain function (see below).
Time Frame
Within five study years
Secondary Outcome Measure Information:
Title
Localization of on-going neural activity during various cognitive and affective tasks
Description
Acquired with fMRI imaging
Time Frame
Within one study day
Title
Brain and body glucose uptake
Description
Acquired with PET imaging
Time Frame
Within one study day
Title
Brain and body CB1 availability
Description
Acquired with PET imaging
Time Frame
Within one study day
Title
Brain MOR availability
Description
Acquired with PET imaging
Time Frame
Within one study day
Title
Genes regulating MOR (OPRM1) and D2R (DRD2) expression
Description
Acquired with whole blood sample and DNA/RNA analysis
Time Frame
Within one study week
Title
Genetic risk score from all known obesity-risk genes
Description
Acquired with whole blood sample and DNA/RNA analysis
Time Frame
Within one study week
Title
Behavioural patterns involving dysfunctional reward learning and inhibitory control
Description
Acquired with following questionnaires: assessment of leisure-time physical activity (LTPA), Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire, Pain Sensitivity Questionnaire, DASS-21, PSS-10
Time Frame
Within one study year
Title
Physical activity level
Description
Acquired with Polar M600 GPS Sports Watch that study subjects wear for the measurement period
Time Frame
Within one study week
Title
Maximal physical performance
Description
The subjects will perform a maximal aerobic exercise test on a bicycle ergometer starting at the intensity of 50 W and followed by an increase of 30 W every 2 min until volitional exhaustion. Peak workload will be calculated as an average workload during the last 2 min of the test (weighted average will be used if the final stage is stopped prior the completion) and used as a measure of maximal performance of the subjects
Time Frame
Within one study day
Title
Physical strength
Description
Total physical strenght score is calculated from 1) countermovement jump test with a contact mat (flight time measured - jump height calculated), hand grip strength (measured in Newtons), sit-ups (number of repetitions in 30 s), and back extension (reps in 30 s)
Time Frame
Within one study day
Title
BMI change in five years
Description
Acquired with BMI of the study subjects measured in initial health check-up and once in every study year
Time Frame
Within five study years
Title
Body adiposity
Description
Acquired with BodPod device (Frisard, Greenway, & DeLany, 2005)
Time Frame
Within one study day
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Inclusion criteria for low-risk group:
Male sex
Age 20-35 years
BMI 20-24 kg/m2
Physical exercise > 4 hrs per week
No maternal / paternal obesity OR maternal / paternal type 2 diabetes mellitus (T2DM)
Inclusion criteria for high-risk group:
Male sex
Age 20-35 years
BMI 25 - 30 kg/m2
Maternal / paternal obesity OR maternal / paternal T2DM
Physical exercise < 4 hrs per week
Exclusion Criteria:
Any chronic disease or medication that could affect glucose metabolism or neurotransmission
History of anorexia nervosa, bulimia or other eating disorder (excl. common obesity)
Smoking of tobacco, taking of snuffs, or use of narcotics
Abusive use of alcohol
Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pirjo Nuutila, M.D., Ph.D.
Organizational Affiliation
Turku PET Centre (Turku University Hospital)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Turku PET Centre (Turku University Hospital)
City
Turku
ZIP/Postal Code
20521
Country
Finland
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
15919837
Citation
Frisard MI, Greenway FL, Delany JP. Comparison of methods to assess body composition changes during a period of weight loss. Obes Res. 2005 May;13(5):845-54. doi: 10.1038/oby.2005.97.
Results Reference
background
Learn more about this trial
Neuromolecular Risk Factors for Obesity (PROSPECT)
We'll reach out to this number within 24 hrs